{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:26:16Z","timestamp":1785432376786,"version":"3.56.0"},"reference-count":35,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014408","name":"National Institute of Geriatrics, Rheumatology and Rehabilitation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014408","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/03gz68w66","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Idiopathic inflammatory myopathies (IIMs) are chronic immune-mediated disorders, causing striated muscle weakness and extramuscular symptoms. Real-world, single-centre data are needed to interpret phenotype patterns and evolving therapies. Methods: A single-centre, retrospective cohort study was conducted at the Rheumatology Clinic of the National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland from 1 January 2022 to 31 December 2025. Data included demographics, IIM subtypes, extramuscular involvement, co-existing Sj\u00f6gren disease (SD), biopsy results, autoantibodies, and treatment. Due to sample size, descriptive analysis was used. Results: The study included 35 patients (31.4% men). Mean age was 50.7 years; mean body mass index (BMI) was 26.0 kg\/m2. The cohort consisted of 10 dermatomyositis (DM), one polymyositis (PM), two immune-mediated necrotising myopathy (IMNM), one inclusion body myositis (IBM), 16 anti-synthetase syndrome (ASyS), four juvenile dermatomyositis (JDM), and one clinically amyopathic dermatomyositis (CADM). SD co-occurred in eight cases, including six cases of ASyS. Anti-Jo1 was observed in 13 ASyS cases and one DM. Glucocorticoids (GCSs) were administered in all patients for induction in addition to cyclophosphamide (28.6%), mycophenolate mofetil (MMF) (51.4%), and methotrexate (MTX) (17.1%). Maintenance therapy included MTX (20%), MMF (31.4%), rituximab (34.3%), azathioprine (AZA) (42.9%), and others. Two DM, two JDM, and one ASyS patient received JAK inhibitors, one DM and one JDM anifrolumab, one IBM sirolimus, and four patients with interstitial lung disease (ILD) nintedanib. Conclusions: This Polish single-centre cohort shows effective use of novel therapies for IIM. Sirolimus, JAK inhibitors, and nintedanib were effective. Co-occurrence of SD in ASyS patients requires further research.<\/jats:p>","DOI":"10.3390\/jcm15103658","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:17:42Z","timestamp":1778519862000},"page":"3658","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Idiopathic Inflammatory Myopathies\u2014Treatment Perspective of Highly Specialised Rheumatology Centre"],"prefix":"10.3390","volume":"15","author":[{"given":"Maria","family":"Dutsch-Wicherek","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Szcz\u0119sny","sequence":"additional","affiliation":[{"name":"National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5981-6041","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Wis\u0142owska","sequence":"additional","affiliation":[{"name":"National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(25)00233-9","article-title":"Advances in the classification and management of idiopathic inflammatory myopathies","volume":"24","author":"Raaphorst","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","first-page":"178","article-title":"The classification of myositis: Setting the stage for a universal terminology","volume":"43","author":"Giannini","year":"2025","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.rdc.2025.07.015","article-title":"The mythology of polymyositis","volume":"51","author":"Biliciler","year":"2025","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/art.43038","article-title":"Clinical Characteristics of Anti-Synthetase Syndrome: Analysis From the Classification Criteria for Anti-Synthetase Syndrome Project","volume":"77","author":"Yoshida","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejr.2025.10.011","article-title":"Idiopathic Inflammatory Myositis: Clinical, Laboratory, and Therapeutic Insights from a Retrospective Case Series","volume":"48","author":"Tharwat","year":"2026","journal-title":"Egypt. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.mpmed.2024.09.005","article-title":"Adult idiopathic inflammatory myopathies","volume":"52","author":"Parker","year":"2024","journal-title":"Medicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Milisenda","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.rdc.2025.07.007","article-title":"Management of lung manifestations in idiopathic inflammatory myopathies","volume":"51","author":"Krishnan","year":"2025","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17172","DOI":"10.1038\/s41598-023-44092-9","article-title":"Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: A retrospective cohort study in Japan","volume":"13","author":"Hu","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s10067-026-07971-w","article-title":"Early detection and intervention in dermatomyositis: Current evidence and clinical implications","volume":"45","author":"Treasure","year":"2026","journal-title":"Clin. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00403-025-04511-5","article-title":"Anti-TIF1-\u03b3-positive dermatomyositis: Novel biomarkers for cancer risk stratification","volume":"318","author":"Koumprentziotis","year":"2026","journal-title":"Arch. Dermatol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10238-024-01300-8","article-title":"Treatment strategies in MDA5-positive clinically amyopathic dermatomyositis: A single-center retrospective analysis","volume":"24","author":"Hirsch","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1007\/s00415-023-11878-w","article-title":"Inclusion body myositis with early onset: A population-based study","volume":"270","author":"Lindgren","year":"2023","journal-title":"J. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.rdc.2025.07.005","article-title":"Updates on diagnostic criteria of inclusion body myositis","volume":"51","author":"Naddaf","year":"2025","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5513544","DOI":"10.1155\/2021\/5513544","article-title":"The Significance of Autoantibodies in Juvenile Dermatomyositis","volume":"2021","author":"Kwiatkowska","year":"2021","journal-title":"BioMed Res. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.55563\/clinexprheumatol\/56ilob","article-title":"Juvenile dermatomyositis. Where are we now?","volume":"40","author":"McCann","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-019-0871-4","article-title":"Juvenile Dermatomyositis-Clinical Phenotypes","volume":"21","author":"Li","year":"2019","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pilato, A., D\u2019Avanzo, G., Di Nunzio, F., Marino, A., Gallo, A., Genovali, I., Corcia, L.P.D., Taffon, C., Perrone, G., and Liakouli, V. (2025). Co-occurrence of anti-synthetase syndrome and Sj\u00f6gren disease: A case-based review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155395"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Konen, F.F., G\u00fczeloglu, Y.E., Seeliger, T., Jendretzky, K.F., Nay, S., Grote-Levi, L., Schwenkenbecher, P., Gr\u00fcndges, C., Ernst, D., and Witte, T. (2025). Idiopathic inflammatory myopathy associated with Sj\u00f6gren\u2019s disease: Features of a distinct clinical entity. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1654576"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.31138\/mjr.29.2.92","article-title":"Sj\u00f6gren syndrome associated with inflammatory muscle diseases","volume":"29","author":"Migkos","year":"2018","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3904\/kjim.1997.12.2.176","article-title":"Clinical significances of antibodies to Ro\/SS-A autoantigens and its subtypes in primary Sj\u00f6gren\u2019s syndrome","volume":"12","author":"Cho","year":"1997","journal-title":"Korean J. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13075-024-03310-z","article-title":"Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies","volume":"26","author":"Campochiaro","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zhen, C., Hou, Y., Zhao, B., Ma, X., Dai, T., and Yan, C. (2022). Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1051609"},{"key":"ref_29","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: A systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"152474","DOI":"10.1016\/j.semarthrit.2024.152474","article-title":"Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: A retrospective cohort study","volume":"68","author":"Shan","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/pde.16012","article-title":"Anifrolumab in refractory juvenile dermatomyositis","volume":"43","year":"2026","journal-title":"Pediatr. Dermatol."},{"key":"ref_32","first-page":"e66704","article-title":"A novel treatment for skin manifestations in dermatomyositis: A case report","volume":"16","author":"Haikal","year":"2024","journal-title":"Cureus"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/WCO.0000000000001393","article-title":"Inclusion body myositis\u2014What are new lines of pathogenesis and therapy?","volume":"38","author":"Krause","year":"2025","journal-title":"Curr. Opin. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e005176","DOI":"10.1136\/rmdopen-2024-005176","article-title":"Efficacy and safety of pharmacological treatments in inclusion body myositis: A systematic review","volume":"11","author":"Santos","year":"2025","journal-title":"RMD Open"},{"key":"ref_35","first-page":"316","article-title":"Optimism in inclusion body myositis: A double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale","volume":"43","author":"Badrising","year":"2025","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3658\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:37:38Z","timestamp":1778560658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15103658"],"URL":"https:\/\/doi.org\/10.3390\/jcm15103658","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]}}}